From Medscape Oncology

European Crohn's and Colitis Organisation (ECCO) 2022 Congress

February 16 - 19, 2022; Virtual

February 16 - 19, 2022 Virtual

ECCO 2022 Two Studies Shed Light on IBD Treatment After Anti-TNF Failure Separate studies compared vedolizumab with tofacitinib in ulcerative colitis and to ustekinumab in Crohn's disease.
Medscape Medical News, February 24, 2022
ECCO 2022 Two Factors Linked to Higher Risk of Long COVID in IBD Researchers behind the large Danish population study reporting these associations said they merit attention from those treating patients with IBD.
Medscape Medical News, February 18, 2022

Vedolizumab Doesn't Increase Risk of C diff in Ulcerative Colitis Vedolizumab's effects in the intestines have led to concerns that the antibody could increase the risk of C difficile infection in patients with ulcerative colitis.
Medscape Medical News, Dec 28, 2021
Real-World Practice Informs Tofacitinib Use in UC Real-world data and practice observations provide further insight into the effective use of the JAK inhibitor in moderate-to-severe ulcerative colitis.
Medscape Medical News, Jan 06, 2022
Risankizumab Has Early and Lasting Benefits in Crohn's Disease Risankizumab takes effect within the first few weeks and has enduring effects in Crohn's disease, phase 3 trials suggest.
Medscape Medical News, Oct 27, 2021

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage

Related Resources